Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. - Wikidata - awgldk - TriplyDB

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.

http://www.wikidata.org/entity/Q34596369

about

Recent progress in pancreatic cancer Systemic Chemotherapy in Advanced Pancreatic Cancer Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians Genetic factors affecting patient responses to pancreatic cancer treatment Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma.Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.Pancreatic cancer: pathobiology, treatment options, and drug delivery.Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study A phase I study of an oral simulated FOLFOX with high dose capecitabine.Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.Pancreatic adenocarcinoma Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas Systemic therapy for metastatic pancreatic adenocarcinoma.A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603).Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials.A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.Adjuvant and neoadjuvant treatment in pancreatic cancer A 71-year-old man with a large cystic pancreatic mass.Pancreatic Cancer: Progress in Systemic Therapy.Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy.Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer.Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?Optimum chemotherapy in the management of metastatic pancreatic cancer Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy.The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.Advanced stage pancreatic cancer: novel therapeutic options.Pancreatic cancer: diagnosis and treatments.Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure.

P2860

Q24626346-2BD01C7E-0076-457E-AF0F-688B8C826E2A Q26750440-0443EA94-52E5-4BA3-8425-17FCBDE6A2A2 Q26767041-4FC9EA7A-8B9E-41E4-B7F1-0A268A8D8695 Q28075293-C82AD59A-1BC4-4A09-AA3D-7AAEA4D8B1FA Q28077772-2305A895-2EBA-4311-BA25-56CA539375E3 Q30315797-7EBFFE21-756B-4D08-A78E-5823C73AAE81 Q33394190-E8D6E589-BA07-4D29-A025-04FFFBCEDA9E Q33422070-0F0B2E8E-8BFB-4526-A441-4419FC1EB32B Q33632330-6F7D8E9D-E58D-425A-B48C-18FE896FBDEE Q33632628-A3F083A2-015D-4295-ABBC-1E4B4712CFED Q33749460-126297FE-AB50-4779-9F6A-2291C85764F6 Q33751227-343D21AF-1DF7-47CA-A692-7D2B6B9E5739 Q33823212-4DE9E016-C1DD-4A93-AB49-70BE1BF2E662 Q33973344-1E3F6784-0DFF-441B-A8FD-E7EB39F151EF Q34122822-A75EC41B-D2F3-4049-93AE-64454A4038D5 Q34140498-F0FECCC0-D837-4723-9269-9D9D48BD9EC1 Q34275000-96F68C8F-6990-4F94-8EBC-C953543BFF78 Q34449812-8157C8C4-BCD2-4A09-B359-5853CFDAFDE6 Q35076238-6C652F71-74B8-4D2B-9DAE-F9E28976B848 Q35583855-ADF594DE-7C61-4C3D-8445-13CE73CA9A06 Q35632548-6769161B-B6E8-4D22-9148-EC8CF97EC4CE Q35703105-19FB2555-FF6E-4705-B5C3-FC629166B73E Q35872109-7B375A76-655C-445C-84B7-12CBC27A85FE Q35886631-89F2E9F3-8A33-4FCC-9736-E6BF161542C1 Q35948154-76788BAD-EBE3-44B4-9F7C-F46EEDB6DFC1 Q36344551-2ED80DA0-0E0A-435D-86AF-ABDBAA940D5C Q36666663-91A6B294-BC5D-44FF-B08E-38BB8704304C Q36733001-99CF005E-DBC3-4ECD-868D-993D066BA7DB Q36892277-24AB95E4-D70E-44ED-979B-F44CDDE05302 Q37032865-CC7D8DFE-EEF9-4A35-BA7B-C5879521562B Q37252144-2854DF20-A5A2-4F1D-B57C-64205D1BCB0B Q37424087-A4737611-B20E-437A-853D-5949FE5B63E4 Q37617955-2E1D1CEF-249E-4512-9C3D-C7F218951668 Q37617976-9A7645D0-6818-41C2-A6D5-52463846054C Q37696059-320B2E33-CF10-441F-A317-F7DA83FB26F7 Q37698616-52E16173-7E18-4567-B0D8-EC1F256DE692 Q38104309-6FBD0F80-0ACA-4548-9317-ADD195D480A6 Q38221089-2893B153-6394-4FBB-853B-92CC49C3EA27 Q38354856-E02793F7-C52A-446A-85BD-440B529C93A5 Q38577917-D916BB16-3C85-4BF4-9B4E-C54ED8094CEF

P2860

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer.

http://www.wikidata.org/entity/Q34596369

description

2008 nî lūn-bûn

@nan

2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase 2 trial of oxaliplatin p ...... th advanced pancreatic cancer.

@ast

Phase 2 trial of oxaliplatin p ...... th advanced pancreatic cancer.

@en

Phase 2 trial of oxaliplatin plus capecitabine

@nl

type

label

Phase 2 trial of oxaliplatin p ...... th advanced pancreatic cancer.

@ast

Phase 2 trial of oxaliplatin p ...... th advanced pancreatic cancer.

@en

Phase 2 trial of oxaliplatin plus capecitabine

@nl

prefLabel

Phase 2 trial of oxaliplatin p ...... th advanced pancreatic cancer.

@ast

Phase 2 trial of oxaliplatin p ...... th advanced pancreatic cancer.

@en

Phase 2 trial of oxaliplatin plus capecitabine

@nl

P1433

Q34596369-49BE51DC-21F2-47C2-9AB5-82306A6C6418

P1476

Q34596369-AB6A5FF6-C0AF-47A9-8F03-C7BD780911C7

P2093

Q34596369-0E42EBE0-4092-4EF6-9E51-6F0BDD6A6528

Q34596369-2953FC54-21F9-4597-8636-17A1B9F2ABB3

Q34596369-2A3C1F0C-AE8E-488F-AD6B-177F98191A3F

Q34596369-833359D3-FEB6-4404-9675-12F0CF015DA2

Q34596369-C6262428-C545-4058-88E0-3076644BBB13

Q34596369-FA471F0A-6A98-4EF5-A454-4E168A267163

P304

Q34596369-4A7FFABB-0F65-4212-B758-705F0DF96755

P31

Q34596369-09DDE3E9-55ED-4D92-AE64-2B9B0A77379E

P356

Q34596369-6369D704-C6E5-4C4F-A886-F4F688F225BF

P407

Q34596369-3A0586C3-4AA8-4FBB-965F-9AE6A262D62F

P433

Q34596369-4AE00F60-FA37-4EB0-BAEC-DEF3C73BEA5D

P478

Q34596369-90E3674D-AFCD-4EC1-A4C6-2CB9604E23C3

P577

Q34596369-FC76F150-7398-411A-8DC5-4D895820577E

P5875

Q34596369-535C2F42-6AB9-4258-8313-751410BEBD97

P698

Q34596369-D35458EB-4B8F-44D3-A611-ED954A4E1FDA

P921

Q34596369-C209AA24-BC09-4525-A979-8B3433877D60

P356

P1433

P1476

Phase 2 trial of oxaliplatin p ...... th advanced pancreatic cancer.

@en

P2093

Gauri R Varadhachary

http://www.w3.org/2001/XMLSchema#string

Henry Q Xiong

http://www.w3.org/2001/XMLSchema#string

James L Abbruzzese

http://www.w3.org/2001/XMLSchema#string

Joan C Blais

http://www.w3.org/2001/XMLSchema#string

Kenneth R Hess

http://www.w3.org/2001/XMLSchema#string

Robert A Wolff

http://www.w3.org/2001/XMLSchema#string

P304

2046-2052

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.23810

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23222891

http://www.w3.org/2001/XMLSchema#string

P698

18756532

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial